5'-methylschweinfurthin G reduces chondrosarcoma tumor growth 

Area of Science:

• Orthopaedic Research
• Oncology
• Pharmacology

Background:

• Chondrosarcomas, especially those with a hyaline cartilage-like matrix, are challenging to treat due to drug resistance and potential for high-grade progression.
• Novel therapeutic strategies are urgently needed for intermediate- to high-grade chondrosarcomas.

Purpose of the Study:

• To investigate the efficacy of 5'-methylschweinfurthin G (MeSG) as a tumor suppressor agent against Swarm rat chondrosarcoma.

Main Methods:

• In vitro studies assessed chondrosarcoma cell proliferation and cytotoxicity sensitivity to MeSG.
• In vivo studies involved treating tumor-bearing mice with MeSG to evaluate tumor growth, morphology, and regression.

Main Results:

• Chondrosarcoma cells exhibited high sensitivity to MeSG (IC50 = 35 nM), significantly more than normal chondrocytes (IC50 = 11 µM).
• MeSG treatment in mice led to reduced tumor growth, an 83% decrease in tumor mass, and complete tumor elimination in 30% of subjects.
• MeSG significantly decreased tumor cell proliferation and increased cell death in treated mice compared to controls.

Conclusions:

• 5'-methylschweinfurthin G demonstrates significant effectiveness in treating rat chondrosarcomas in an animal model.
• MeSG shows potential as a therapeutic option for difficult-to-treat intermediate- to high-grade hyaline cartilage-like chondrosarcomas.